LCM
AIMT

Laurion Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Laurion Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,000
Closed -$149K – 1112
2016
Q1 		$149K Buy
+11,000
New +$172K ﹤0.01% 706

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Laurion Capital Management's AIMT Position: Q2 2016 in Review

Laurion Capital Management sold out of Aimmune Therapeutics (AIMT) in Q2 2016, closing a stake of 11,000 shares — an estimated $149K sold.

Laurion Capital Management first reported a position in AIMT in Q1 2016 and held it in 1 quarter. The position peaked at $149K in Q1 2016. 74 funds tracked by Wall St. Rank hold AIMT as of Q2 2016.

  • Laurion Capital Management reported no remaining Aimmune Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Laurion Capital Management sold 11,000 Aimmune Therapeutics shares in Q2 2016, an estimated $149K.
  • Laurion Capital Management first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 1 quarter.
  • Laurion Capital Management's Aimmune Therapeutics position peaked at $149K in Q1 2016.
  • 74 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2016.

Based on Laurion Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.